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Sir,
In the March 8 issue, Ohwada et al (2004) reported a randomised
study of patients with stage II or III colorectal cancer, treated with
either UFT alone or the combination of UFT and PSK. The benefit
obtained by PSK seems impressive, with a decrease by 43.6% in the
risk of recurrence and 5-year disease-free survival of 73%, especially
as there were only 139 patients in the investigational group and 68 in
the control group. Nevertheless, several aspects must be discussed.
The first point is the choice of the control arm. The combination of
5-FU and leucovorin currently is the standard adjuvant chemotherapy
of colorectal cancer in most countries. There is currently no evidence
that UFT, even when modulated by leucovorin, is superior to this
regimen. On the contrary, a large phase III trial comparing UFT/
leucovorin with 5-FU/LV (Mayo Clinic regimen) in 816 patients with
metastatic disease resulted in an increase by 22% in the risk of disease
progression in the investigational arm (Douillard et al, 2002). Another
randomised study showing some benefit in terms of survival for
cancer death only used oral 5-FU in the control arm (Ito et al, 2004).
Of note is the high proportion of patients with rectal cancer, reaching
50% in the control group. Given the impact of the quality of surgery
and radiotherapy in this location, a confusing factor might have been
introduced especially as preoperative radiotherapy has not been
administered. The study design introduces several variables in
chemotherapy such as early start, long duration, sequential admin-
istration of MMC and UFT, introducing other confusing factors. The
early start of chemotherapy might be interesting since surgery
provokes the circulation of neoplastic cells (Yamaguchi et al, 2000)
and angiogenesis and potentially the development of micrometastasis.
Intravenous chemotherapy usually starts 4–8 weeks after surgery.
Nevertheless, the poor results of the control arm do not support this
approach. On a psychological viewpoint, the impact of a very long
treatment should not be neglected since it may enforce the idea that
cancer can relapse any time. The results in stage III patients in the
control arm are poor and question about the efficacy of UFT and
MMC. Indirectly, the mediocrity of UFT alone minimises the impact
of PSK. The authors largely invoke indirect comparisons with
studies published more than 10 years before while many
procedures, including surgery, improve over time and promising
trials of combination chemotherapy with either oxaliplatin or
irinotecan are ongoing. The impact of secondary surgery as well as
second-line chemotherapy in well-followed patients may be
important in terms of overall survival. The issue of the mechanism
of action of PSK, in particular its synergy with a fluoropyrimidine,
is intriguing. Since decades, a tremendous number of studies
regarding immunotherapy have been reported. Although extracts of
microbial agents can logically induce demonstrable production of
interleukin-2, interferon, or activated immune cells, evidence of a
clinical impact remains extremely limited. Even high-dose inter-
leukin-2 or interferon result only in a modest efficacy in subgroups
of patients with cancers partially dependant on immunesurveillance
such as advanced renal cancer or melanoma. The efficacy of
interferon in the adjuvant therapy of melanoma is highly debated
(Sabel and Sondak, 2003). Recent randomised studies have shown
that neither interferon (Messing et al, 2003) nor interleukin-2 (Clark
et al, 2003) improve survival in the adjuvant treatment of high-risk
renal carcinoma. Consequently, the impact of ‘soft’ immunotherapy
is difficult to advocate in colorectal cancer. In addition, several
recent randomised studies have called into question the efficacy of
levamisole (QUASAR Collaborative Group, 2000; Dencausse et al,
2002; Cascinu et al, 2003). Probably, an alternative mechanism
should be considered. Inhibition of metastases by protection of
vascular membrane basement has also been evoked (Kudo et al,
2002). In conclusion, although PSK remains a good candidate for
convenient adjuvant therapy, this study is not definitively convin-
cing. The challenge remains crucial since oral therapy is particularly
adapted to the vast concerned population, particularly in the elderly,
given the relatively heavy procedure of combination chemotherapy
with FOLFOX or FOLFIRI regimen.
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Sir,
We thank Dr C Alliot for his comments and critique in the
editorial accompanying our article (Ohwada et al, 2004). Regarding
the choice of the control arm, we agree that the standard adjuvant
treatment for stage III colon cancer since 1990 has been 5-
fluorouracil plus leucovorin (5-FU/LV) (NIH, 1990; IMPACT, 1995;
Wolmark et al, 1999). Now, FOLFOX has become a standard
regimen for stage II or III colorectal cancer (Andre et al, 2004).
Nevertheless, the Ministry of Health and Welfare of Japan did not
approve LV for colorectal cancer until June 16, 1999. This study
was conducted between October 1994 and March 1997, 2 years
before official permission. Therefore, LV was unavailable as a
randomised control. As you indicated, there is currently no
evidence that UFT is superior to the standard regimen, even when
modulated by LV. In a large phase III trial that compared UFT/LV
with 5-FU/LV for untreated metastatic colorectal cancer, UFT/LV
was found to be a safer, more convenient oral alternative to a
standard bolus IV 5-FU/LV regimen, while producing equivalent
survival; however, it was associated with an inferior time to disease
progression and 22% increase in the risk of disease progression
(Douillard et al, 2002). Recently, the efficacy of UFT has been
determined. In randomised, controlled trials, adjuvant chemother-
apy with UFT alone improved the survival of patients with
completely resected pathological stage III rectal cancer (Akatsu
et al, 2004) and stage I adenocarcinoma of the lung (Kato et al,
2004), compared with surgery alone.
Dr Alliot was concerned with the high proportion of patients
with rectal cancer in the control arm, the impact of the quality of
surgery, and the fact that no preoperative radiotherapy was
administered. The 5-year disease-free survival for rectal cancer was
69.4% (95% CI: 56.5–82.3%) with PSK and 52.9% (95% CI: 36.2–
69.7%) in the controls (P¼0.133). The difference was not
significant, but the high proportion of patients with rectal cancer
in the control arm may have pushed the survival for all the patients
downward. Therefore, we reanalysed the 5-year disease-free
survival adjusted for histologic type and tumour location and
found that the survival remained significantly better for the PSK
group (stratified logrank; P¼0.031). The result suggests that the
high proportion of patients with rectal cancer did not affect the
survival significantly.
As Dr Alliot indicated, the quality of surgery is an important
point when conducting any randomised, controlled trial in a
surgical field. The recognition that tumour cell involvement in the
circumferential margin is important in local recurrence has led to
the general use of total mesorectal excision (MacFarlane et al,
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